男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Asia-Pacific

Japan approves rollout of protein-based Novavax COVID-19 vaccine

Xinhua | Updated: 2022-04-19 14:07
Share
Share - WeChat
A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken Jan 11, 2021. [Photo/Agencies]

TOKYO - Japan's health ministry on Tuesday approved the use of a COVID-19 vaccine developed by US pharmaceutical company Novavax to be used on people aged 18 and older.

The Novavax vaccine will mark the fourth COVID-19 inoculation approved in Japan, although will be the first protein-based vaccine compared to those developed by Pfizer and Moderna that are messenger RNA-based (mRNA) jabs.

The ministry hopes the Novavax jab can be administered to those who are likely to show allergic reactions to mRNA vaccines so they can still be vaccinated against the virus which has yet to be brought under control in Japan.

According to Japan's public broadcaster NHK, protein-based vaccines are known to cause relatively fewer reactions, with the thinking being among the ministry that this will help the uptake of those who are as yet unvaccinated because they have been worried about side effects.

The Novavax vaccine requires recipients to be jabbed twice with a three-week period between doses, the ministry said, although a third booster shot will be allowed six months or more after the second jab.

Takeda Pharmaceutical will manufacture the jab locally and distribute the Novavax vaccine and is under contract to supply 150 million doses of the vaccine to the government within a year, according to official accounts.

The rollout, they said, is expected to begin in late May, with Health Minister Shigeyuki Goto saying on Tuesday that the government purchased the vaccine last September to make sure Japan was in possession of a stable supply should restrictions be applied on overseas vaccines.

Goto also said Novavax as a vaccine also got the green light from the government specifically because it is protein-based and is regarded as safe and effective.

He added that the Japanese government had always intended to procure a variety of different vaccines so as to offer the public more choices.

Local governments have been asked by the health ministry to open at least one site where the Novavax vaccine can be administered to make sure that those who prefer the protein-based jab, or require a non-mRNA for whatever reason, have access to it.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 双桥区| 台南市| 绿春县| 涞源县| 郴州市| 辽中县| 东山县| 手机| 铜山县| 灌南县| 莱西市| 万年县| 许昌县| 星子县| 岢岚县| 深州市| 宜兰县| 潮安县| 武宁县| 广宗县| 汉阴县| 上林县| 鹤山市| 伊吾县| 肥城市| 吉木乃县| 南木林县| 长垣县| 玉田县| 应城市| 东港市| 乃东县| 于都县| 巫溪县| 铁岭市| 昆山市| 松滋市| 太白县| 仪征市| 德保县| 马龙县|